[68Ga]-LNTH-2401

[68Ga]-LNTH-2401 (formerly known as 68Ga-RM2 or 68Ga-DOTA-RM2) is a clinical-stage radiodiagnostic radiopharmaceutical developed by Lantheus. It is a gallium-68 (68Ga)-labeled positron emission tomography (PET) tracer whose active ingredient is the DOTA-RM2 peptide, which acts as an antagonist targeting the gastrin-releasing peptide receptor (GRPR). GRPR is overexpressed in several solid tumors, including prostate and breast cancers. [68Ga]-LNTH-2401 is being developed primarily for the diagnosis and staging of prostate cancer (both newly diagnosed and biochemically recurrent) and serves as a companion diagnostic to the therapeutic radiopharmaceutical LNTH-2402 (177Lu-RM2). Lantheus acquired global rights to the RM2 program from Life Molecular Imaging in June 2024.

Other names

68Ga-DOTA RM268Ga-DOTA-RM268Ga-RM2[(68)Ga]-labelled bombesin[68GA]DOTA-4-AMINO-1-CARBOXYMETHYLPIPERIDINE-D-PHE-GLN-TRP-ALA-VAL-GLY-HIS-STA-LEU-NH2[68Ga]RM2Bombesin (68Ga) labelledGallium-68 RM2Gallium68 RM2Gallium 68 RM2Gallium-68-bombesinGallium68-bombesinGallium 68-bombesinGallium-68-labeled GRPr AntagonistGallium68-labeled GRPr AntagonistGallium 68-labeled GRPr Antagonist